In the context of therapeutic trials in development for myotonic dystrophy type 1 (DM1), the search for reliable and relevant clinical or paraclinical criteria is still ongoing. A group of British researchers has focused on one of them specifically.
- The volume of the masseter muscle was assessed on imaging (brain MRI) in 39 patients with DM1.
- It was then compared with that of a control group of 20 healthy volunteers.
- Correlation studies with other parameters used in DM1 (CTG expansion size, MIRS functional score) show the interest of this new biomarker.
The evaluation of the atrophy of this facial muscle could thus constitute a good element, especially in the context of future trials.
